Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 209 Stomach Neoplasms 37 Neoplasm Metastasis 26 Neoplasms 18 HER2-positive Breast Cancer 14 Colorectal Neoplasms 14 Carcinoma, Non-Small-Cell Lung 10 Brain Neoplasms 10 Esophageal Neoplasms 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Endometrial Neoplasms 4 Adenocarcinoma Of Esophagus 4 Uterine Cervical Neoplasms 3 Urologic Neoplasms 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 HER2-positive Gastric Cancer 3 Carcinoma 3 Breast Cancer Metastatic 3 Urinary Bladder Neoplasms 2 Solid Tumors 2 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Melanoma 2 HER2-positive Early Breast Cancer 2 Cholangiocarcinoma 2 Breast Diseases 2

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Osteitis Deformans × Trastuzumab × Clear all

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡